Borders College

PAD^TM is the result of more than twenty years work, initially at the Eastman Dental Institute, University College London and since 2000 by Denfotex. PAD^TM was first marketed for endo disinfection in 2003 and has been used very successfully, mainly by GDP’s in the UK, Germany and the Middle East. The clinical performance of PAD^TM is the subject of an ongoing independent single blind trial started in 2002 with currently over 400 patients enrolled, including over 60 cases that did not respond to conventional endodontic therapy. The trial is based at a clinical practice in Aberdeen and the bacterial load in canals is measured both before and after best conventional treatment with hypochlorite, and then again after PAD^TM , after which the number of disinfected canals increases from ~ 80% to 100%. Significantly, all the re-treatments recovered after PAD^TM . The overall results show a success rate in excess of 99.9%. The trial has been reported in the British Dental Journal on two occasions by Bonsor, Nichol, Reid & Pearson.